Evidence map›Paper›PMID 40329036›Full record

ArticleDrug delivery and translational research2025

Post-encapsulation methods for the preparation of mRNA-LNPs.

Joanna Duffrène, Chloé Muzard, Johanne Seguin, Charlotte Izabelle, Thibaut Vrai, Tina Ejlalmanesh, Marianne Bombled, Samir Hamdi, Katia Lemdani, Khair Alhareth and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joanna Duffrène *Université Paris Cité, CNRS, INSERM, Unité des Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, 75006, France.ORCID 0009-0008-2527-6552
Chloé Muzard *Université Paris Cité, CNRS, INSERM, Unité des Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, 75006, France.ORCID 0009-0001-3417-2965
Johanne SeguinUniversité Paris Cité, CNRS, INSERM, Unité des Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, 75006, France.ORCID 0000-0003-3359-6202
Charlotte IzabelleUniversité Paris Cité, INSERM, CNRS, Plateforme d'Imagerie Cellulaire et Moléculaire (PICMO), Paris, 75006, France.
Thibaut VraiNeovacs SA, Suresnes, France.
Tina EjlalmaneshNeovacs SA, Suresnes, France.
Marianne BombledUniversité Paris Cité, CNRS, INSERM, Unité des Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, 75006, France.
Samir HamdiNeovacs SA, Suresnes, France.
Katia LemdaniNeovacs SA, Suresnes, France.ORCID 0000-0002-7222-6151
Khair Alhareth *Université Paris Cité, CNRS, INSERM, Unité des Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, 75006, France. khairallah.alhareth@u-paris.fr.ORCID 0000-0001-5976-6594
Nathalie Mignet *Université Paris Cité, CNRS, INSERM, Unité des Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, 75006, France. nathalie.mignet@u-paris.fr.ORCID 0000-0002-3323-2997

Funding

Agence Nationale de la Recherche 22-PEBI-0007
6 · The paper itself

Abstract

Microfluidics mixing is the current lab-scale method used for producing mRNA-loaded lipid nanoparticles (mRNA-LNPs) thanks to reproducibility and robustness of microfluidic mixing. Despite these advantages, the production of small LNP volumes is associated with significant material waste. Given the high cost of synthetic mRNA, this waste can be a major limitation, particularly for early-stage screening of formulations. This study proposes alternative methods for mRNA-LNP formulation aiming to improve their stability for both formulation and mRNA screening, while reducing material waste on a research scale. Specifically, we investigated post-encapsulation of mRNA into pre-formed vesicles (PFVs) obtained by microfluidic mixing. These PFVs were complexed with mRNA by: (1) a microfluidic or (2) a manual pipetting method. The resulting mRNA-LNPs produced using these two post-encapsulation methods exhibit similar physicochemical properties and morphologies to those obtained by conventional microfluidic protocol. These mRNA-LNPs were assessed on in vitro and in vivo expression. mRNA-LNPs prepared by our alternative methods showed a similar transfection level compared to the conventional formulation taken as a control. The suitability of post-encapsulation methods to other lipids, mRNAs and microfluidic systems was also confirmed. This work offers robust, simple and economic alternative methods for preparing small volumes of mRNA-LNPs. The versatility of post-encapsulation methods allows to screen mRNA formulations in a wide range of laboratories. These methods could be applied to encapsulate tailored doses of mRNA and various mRNA constructs to achieve an optimal and personalized therapy.

Indexed as

LipidsNanoparticlesRNA, MessengerAnimalsHumansLiposomesMiceMicrofluidicsLipid NanoparticlesLipidsLiposomesRNA, MessengerLipid nanoparticlesMicrofluidicmRNA deliverymRNA integrityNanomedicinePost-encapsulation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.